Critical evaluation of the efficacy and tolerability of azilsartan

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 299-305

  De Caterina, Alberto Ranieri ^a,b   Harper, Andrew R ^b,c   Cuculi, Florim ^b  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Angiotensin receptor blocker; Azilsartan medoxomil; Hypertension

Indexed keywords

AMLODIPINE; ANTACID AGENT; AZILSARTAN; AZILSARTAN MEDOXOMIL; CAFFEINE; CANDESARTAN; CANDESARTAN HEXETIL; CHLORTALIDONE; DEXTROMETHORPHAN; DIGOXIN; EPROSARTAN; FEXOFENADINE; FLUCONAZOLE; GLIBENCLAMIDE; IRBESARTAN; KETOCONAZOLE; LOSARTAN POTASSIUM; METFORMIN PLUS PIOGLITAZONE; MIDAZOLAM; OLMESARTAN; PLACEBO; TELMISARTAN; TOLBUTAMIDE; VALSARTAN; WARFARIN; 2 ETHOXY 1 ((2' (5 OXO 2,5 DIHYDRO 1,2,4 OXADIAZOL 3 YL) BIPHENYL 4 YL)METHYL) 1H BENZIMIDAZOLE 7 CARBOXYLIC ACID; 2-ETHOXY-1-((2'-(5-OXO-2,5-DIHYDRO-1,2,4-OXADIAZOL-3-YL)-BIPHENYL-4-YL)METHYL)-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; OXADIAZOLE DERIVATIVE;

ALBUMINURIA; AREA UNDER THE CURVE; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MILK LEVEL; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; PRIMARY HEALTH CARE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; DRUG INTERACTION; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY; RISK ASSESSMENT; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; OXADIAZOLES; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84865642487     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S22589     Document Type: Review

References (35)

1. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):2761-2788.
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746-2753.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-223.
4. Guilbert JJ. The world health report 2002 - reducing risks, promoting healthy life. Educ Health (Abingdon). 2003;16(2):230.
5. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513-1518.
6. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens. 2006;24(3):423-430.
7. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25(9):1751-1762.
8. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349(9054):747-752.
9. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
10. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
11. McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll of Cardiol. 2006;47(4):726-733.
12. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759-766.
13. Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103-109. doi:10.1038/nature10405.
14. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensinaldosterone system. Nat Rev Drug Discov. 2002;1(8):621-636.
15. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008;4:CD003823.
16. McManus RJ, Caulfield M, Williams B; National Institute for Health and Clinical Excellence. NICE hypertension guideline 2011: evidence based evolution. BMJ. 2012;344:e181. doi:10.1136/bmj.e181.
17. Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010;121(7):934-939.
18. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review. J Hum Hypertens. 2009;23(8):495-502.
19. Cuculi F, Erne P. Combined neutral endopeptidase inhibitors. Expert Opin on Investig Drugs. 2011;20(4):457-463.
20. Kurtz TW, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8: 133-143.
21. Jones JD, Jackson SH, Agboton C, Martin TS. Azilsartan medoxomil (Edarbi): the eighth angiotensin II receptor blocker. PT. 2011;36(10):634-640.
22. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, doubleblind clinical study. Hypertens Res. 2012. doi:10.1038/hr.2012.8.
23. Zaiken K, Cheng JW. Azilsartan medoxomil: a new angiotensin receptor blocker. Clin Ther. 2011;33(11):1577-1589.
24. Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens. 2011;29(12):2476-2483.
25. Center for Drug Evaluation and Research [website on the Internet]. Silver Spring, MD: NDA 200-796: Azilsartan medoxomil, Clinical Pharmacology and Biopharmaceutics Review(s). 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796Orig1s000ClinPharmR.pdf. Accessed 1 April, 2012.
26. Edarbi.com [homepage on the Internet]. Two options to help lower blood pressure. Deerfield, IL: Takeda Pharmaceuticals America, Inc. 2012. Available from: http://www.edarbi.com/. Accessed 1 April, 2012.
27. Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011;336(3):801-808.
28. French CJ, Zaman AK, Sobel BE. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol. 2011;58(2):143-148.
29. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21(9):1761-1769.
30. Kusumoto K, Igata H, Ojima M, et al. Antihypertensive, insulinsensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol. 2011;669(1- 3):84-93.
31. Zhao M, Li Y, Wang J, et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab. 2011;13(12):1123-1129. doi:10.1111/j.1463-1326.2011.01471.x.
32. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6(10):2364-2373.
33. Segura J, Campo C, Gil P, Roldán C, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol. 2004;15(6):1616-1622.
34. Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13(2):81-88. doi:10.1111/j. 1751-7176.2010.00425.x.
35. Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011;13(7):467-472. doi:10.1111/j.1751-7176.2011.00482.x.